SCHEMBL22096039

SCHEMBL22096039

O=C(O)c1nonc1NCn1nnnc1COCc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 4/20 0.77
KDM4C Q9H3R0 1/20 0.39
GHSR Q92847 7/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
EGLN1 Q9GZT9 1/20 0.33
ATM Q13315 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096037 0.91 STAT5B (0.73) STAT5BKDM4CGHSRALDH1A1CYP1A2
SCHEMBL20048221 0.87 STAT5B (1.00) STAT5BKDM4CALDH1A1CYP1A2CYP2C9
SCHEMBL22096035 0.86 STAT5B (0.72) STAT5BKDM4CALDH1A1CYP1A2CYP2C9
SCHEMBL22096030 0.86 STAT5B (0.82) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22096031 0.84 STAT5B (0.78) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL20047849 0.84 STAT5B (0.78) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22096032 0.84 STAT5B (0.78) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22096011 0.81 STAT5B (0.88) STAT5BALDH1A1HDAC6
SCHEMBL22096012 0.81 STAT5B (0.83) STAT5BKDM4CALDH1A1
SCHEMBL22096036 0.80 STAT5B (0.69) STAT5BKDM4CALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885KDM4C 1031/4885GHSR 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.